This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Jul 24;376(9737):211-3.

doi: 10.1016/S0140-6736(10)61119-1.

PARP inhibition in BRCA-mutated breast and ovarian cancers

Stephen L Chan¹, Tony Mok

Affiliations

Affiliation

¹ State Key Laboratory of South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong. l_chan@clo.cuhk.edu.hk

PMID: 20656109
DOI: 10.1016/S0140-6736(10)61119-1

Comment

PARP inhibition in BRCA-mutated breast and ovarian cancers

Stephen L Chan et al. Lancet. 2010.

. 2010 Jul 24;376(9737):211-3.

doi: 10.1016/S0140-6736(10)61119-1.

Authors

Stephen L Chan¹, Tony Mok

Affiliation

¹ State Key Laboratory of South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong. l_chan@clo.cuhk.edu.hk

PMID: 20656109
DOI: 10.1016/S0140-6736(10)61119-1

No abstract available

PubMed Disclaimer

Comment on

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Tutt A, et al. Lancet. 2010 Jul 24;376(9737):235-44. doi: 10.1016/S0140-6736(10)60892-6. Epub 2010 Jul 6. Lancet. 2010. PMID: 20609467 Clinical Trial.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Audeh MW, et al. Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6. Lancet. 2010. PMID: 20609468 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information